# GETUG-AFU22 (NCT01994239)

> Comparison of HT Concomitant With RT vs RT Alone in Patients With a Detectable PSA After Prostatectomy

No report yet. It can be ordered.

- Drugs tested: degarelix
- Indication: prostate adenocarcinoma with detectable PSA after prostatectomy

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01994239
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: UNICANCER
- Conditions: Adenocarcinoma of Prostate
- Interventions: Degarelix; Pelvic Radiotherapy
- Enrollment: 120
- Primary outcome: The efficacy of the combination of hormonal therapy by degarelix and radiotherapy on event-free survival

## Indexed commentary on GETUG-AFU22 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 6 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=getug-afu22-nct01994239